tiprankstipranks
Trending News
More News >
ProQR (PRQR)
NASDAQ:PRQR
Advertisement

ProQR (PRQR) AI Stock Analysis

Compare
1,136 Followers

Top Page

PRQR

ProQR

(NASDAQ:PRQR)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 4o)
Rating:52Neutral
Price Target:
$3.00
▲(6.38% Upside)
ProQR's stock score is primarily impacted by its financial performance challenges, including declining revenue and persistent losses. While technical analysis shows bullish momentum, the negative valuation metrics, such as the P/E ratio, weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Innovative RNA Platform
ProQR's proprietary RNA technology platform provides a strong foundation for developing transformative therapies, offering a competitive edge in addressing genetic diseases.
Clinical Trial Authorization
The authorization for AX-0810's clinical trial marks a significant step in ProQR's pipeline, potentially leading to new treatments for cholestatic diseases, enhancing long-term growth prospects.
High Gross Profit Margin
A high gross profit margin indicates efficient cost management and strong pricing power, which can support long-term profitability as the company scales its operations.
Negative Factors
Declining Revenue
Declining revenue poses a challenge to financial stability and growth, potentially limiting the company's ability to invest in R&D and expand its market presence.
Persistent Losses
Ongoing losses and negative profit margins highlight financial struggles, which may hinder ProQR's ability to sustain operations and fund future development projects.
Negative Operating Cash Flow
Negative operating cash flow indicates cash management challenges, impacting ProQR's ability to finance its operations and invest in growth opportunities without external funding.

ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)

ProQR Business Overview & Revenue Model

Company DescriptionProQR Therapeutics N.V. is a biotechnology company focused on developing transformative RNA medicines for the treatment of genetic diseases. The company operates primarily in the pharmaceutical sector, specializing in innovative therapies designed to address severe genetic disorders. ProQR’s core products include its proprietary RNA technology platform, which is utilized to create treatments aimed at correcting genetic mutations, with a focus on conditions such as cystic fibrosis and Leber congenital amaurosis.
How the Company Makes MoneyProQR generates revenue primarily through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with pharmaceutical companies and research institutions to co-develop therapies, which can provide upfront payments, milestone payments, and royalties on future sales of products developed through these collaborations. Additionally, ProQR may receive funding through grants and investments aimed at advancing its clinical programs. As its drug candidates progress through clinical trials and gain regulatory approvals, the potential for revenue increases significantly, particularly if successful therapies are commercialized.

ProQR Financial Statement Overview

Summary
ProQR faces significant financial challenges, with declining revenue and persistent losses impacting profitability. The balance sheet shows moderate leverage, but negative returns on equity highlight ongoing financial struggles. Cash flow improvements are limited, with negative operating cash flow posing risks to financial stability. Overall, the company needs to address its profitability and cash flow issues to improve its financial health.
Income Statement
35
Negative
ProQR's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a revenue decline of 13.26%, and net profit margins are deeply negative at -158.81%. Despite a high gross profit margin of 96.24%, the company struggles with profitability, as evidenced by negative EBIT and EBITDA margins.
Balance Sheet
45
Neutral
The balance sheet indicates moderate leverage with a debt-to-equity ratio of 0.21 in the TTM period. However, the return on equity is negative at -53.58%, reflecting ongoing losses. The equity ratio is not provided, but the company's financial stability is under pressure due to consistent negative returns.
Cash Flow
40
Negative
Cash flow analysis shows a slight improvement in free cash flow growth at 13.11% in the TTM period. However, operating cash flow remains negative, and the operating cash flow to net income ratio is -1.10, indicating cash flow challenges. The free cash flow to net income ratio is slightly positive at 1.02, suggesting some alignment between cash flow and net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue16.49M18.91M6.51M4.04M1.35M0.00
Gross Profit16.49M18.91M6.38M1.56M1.35M-2.19M
EBITDA-35.70M-24.12M-24.10M-56.46M-54.95M-136.56M
Net Income-39.67M-27.76M-28.12M-64.89M-61.68M-46.61M
Balance Sheet
Total Assets137.54M167.96M137.88M171.32M209.58M98.73M
Cash, Cash Equivalents and Short-Term Investments119.77M149.41M118.92M94.78M187.52M75.84M
Total Debt16.86M17.22M19.73M21.97M60.37M34.28M
Total Liabilities70.55M79.40M96.49M106.21M96.35M42.18M
Stockholders Equity66.98M88.56M41.39M65.50M113.83M57.09M
Cash Flow
Free Cash Flow-42.95M-37.81M20.18M-69.22M-26.50M-47.98M
Operating Cash Flow-42.20M-36.39M21.55M-68.51M-26.01M-47.06M
Investing Cash Flow13.60M-4.07M4.28M-702.00K-425.00K-924.00K
Financing Cash Flow70.18M70.28M-2.27M-30.89M136.83M14.50M

ProQR Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.82
Price Trends
50DMA
2.31
Positive
100DMA
2.20
Positive
200DMA
2.02
Positive
Market Momentum
MACD
0.18
Negative
RSI
60.91
Neutral
STOCH
70.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.49, above the 50-day MA of 2.31, and above the 200-day MA of 2.02, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 60.91 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.

ProQR Risk Analysis

ProQR disclosed 79 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProQR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$238.97M-22.84%6.05%2.24%
52
Neutral
$286.18M-6.35-75.99%7.59%-53.46%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$261.09M-32.38%23.24%
45
Neutral
$218.14M-120.209.78%98.13%
40
Underperform
$231.08M-3.16-111.00%-6.12%24.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRQR
ProQR
2.82
-0.64
-18.50%
CDXS
Codexis
2.59
-0.32
-11.00%
HRTX
Heron Therapeutics
1.19
-0.66
-35.68%
TLSA
Tiziana Life Sciences
1.90
0.91
91.92%
AVIR
Atea Pharmaceuticals
3.19
-0.16
-4.78%
OABI
OmniAb
1.60
-2.15
-57.33%

ProQR Corporate Events

ProQR Receives CTA Authorization for AX-0810 and Plans Investor Event
Oct 20, 2025

On October 20, 2025, ProQR Therapeutics announced that it received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 study of its investigational RNA editing oligonucleotide, AX-0810. This study, to be conducted in the Netherlands, will evaluate the safety, tolerability, and pharmacokinetics of AX-0810, which targets NTCP for the treatment of cholestatic diseases. The company also announced a virtual Investor and Analyst Event scheduled for November 3, 2025, to discuss the clinical development of AX-0810 and its potential impact on treating liver diseases.

ProQR Reports Q2 2025 Financial Results Amid Rising R&D Costs
Aug 7, 2025

On August 7, 2025, ProQR Therapeutics N.V. announced its financial results for the second quarter of 2025, ending June 30. The company reported a decrease in revenue compared to the previous year, alongside increased research and development costs, leading to a significant operating loss. This financial performance may impact ProQR’s market positioning and stakeholder confidence as the company navigates the challenges of developing treatments for rare genetic disorders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025